Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$108.13 USD

108.13
1,465,958

+1.35 (1.26%)

Updated Jul 5, 2024 04:00 PM ET

After-Market: $108.20 +0.07 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 249)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Novartis (NVS) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

Novartis (NVS) closed at $108.03 in the latest trading session, marking a -0.21% move from the prior day.

Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024

by Zacks Equity Research

Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.

Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Annexon, Inc. (ANNX) and Novartis (NVS) have performed compared to their sector so far this year.

Zacks Investment Ideas feature highlights: Eli Lilly and Novartis

by Zacks Equity Research

Eli Lilly and Novartis have been highlighted in this Investment Ideas article.

Bryan Hayes headshot

These Stocks Are Showing Relative Strength as S&P 500 Stalls Near Record High

by Bryan Hayes

As investors, our job isn't to predict an unknowable future.

Novartis (NVS) Stock Drops Despite Market Gains: Important Facts to Note

by Zacks Equity Research

The latest trading day saw Novartis (NVS) settling at $107.45, representing a -0.14% change from its previous close.

Cytokinetics (CYTK) Down on Report of Novartis Not Interested

by Zacks Equity Research

Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.

Novartis (NVS) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Novartis (NVS) closed at $107.60, marking a +0.15% move from the previous day.

Andrew Rocco headshot

Bullish Continuation in '24? 3 Market Areas to Watch

by Andrew Rocco

Will stocks continue into 2024? Stock Strategist Andrew Rocco shares his prediction and unveils 3 important market areas to monitor.

Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis

by Zacks Equity Research

Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.

Merck (MRK) Begins Pivotal Studies on Four Cancer Candidates

by Zacks Equity Research

Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.

The Zacks Analyst Blog Highlights Merck, Salesforce, Philip Morris International, Novartis and CME Group

by Zacks Equity Research

Merck, Salesforce, Philip Morris International, Novartis and CME Group are part of the Zacks top Analyst Blog.

Novartis (NVS) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

In the most recent trading session, Novartis (NVS) closed at $106.31, indicating a +0.7% shift from the previous trading day.

Mark Vickery headshot

Top Analyst Reports for Merck, Salesforce & Philip Morris

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Salesforce, Inc. (CRM) and Philip Morris International Inc. (PM).

NVS or LLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?

Novartis AG (NVS) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Biotech Stock Roundup: VYGR Gains From NVS Deal, AGIO Up on Study Data & More

by Zacks Equity Research

Collaboration news from Voyager (VYGR) and study updates from Agios (AGIO) are the key highlights this week.

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

by Zacks Equity Research

Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.

Novartis (NVS) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

In the closing of the recent trading day, Novartis (NVS) stood at $101, denoting a +0.03% change from the preceding trading day.

Here's Why You Should Retain Humana (HUM) in Your Portfolio

by Zacks Equity Research

Humana (HUM) remains well-poised for growth, attributable to an aging U.S. population, contract wins, acquisitions and expanding cash reserves.

Novartis (NVS) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Novartis (NVS) closed at $99.71 in the latest trading session, marking a +1.18% move from the prior day.

The Zacks Analyst Blog Highlights Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours

by Zacks Equity Research

Procter & Gamble, PepsiCo, Novartis, Occidental Petroleum and DuPont de Nemours are part of the Zacks top Analyst Blog.

Novartis (NVS) Stock Moves -1.17%: What You Should Know

by Zacks Equity Research

Novartis (NVS) closed the most recent trading day at $97.14, moving -1.17% from the previous trading session.

Roche's (RHHBY) sBLA for Xolair Gets FDA Priority Review Tag

by Zacks Equity Research

The FDA accepts and grants priority review to Roche's (RHHBY) supplemental biologics license application for Xolair for the reduction of food allergic reactions. A decision is due in the first quarter of 2024.